# Jabez Biosciences

Source: https://onco.cc/companies/jabez-biosciences/  
OnCo record `jabez-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jabez Biosciences makes JBZ-001, a tablet that blocks an enzyme cancer cells need to build new DNA and RNA building blocks. It is in a first trial in people with advanced solid tumours and non-Hodgkin lymphoma.

## Summary

Jabez Biosciences, Inc., with releases datelined Zionsville, Indiana, describes itself as a lean drug development company that licenses academic discoveries into cancer therapies it calls '3-S' (seamless, scalable, synergistic). Its lead compound JBZ-001 is an oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme of pyrimidine synthesis. A first-in-human phase 1 dose-escalation and expansion trial (NCT06801002) in refractory solid tumours and non-Hodgkin lymphoma dosed its first patient at The Ohio State University Comprehensive Cancer Center in April 2025, added a second site in August 2025, and first-in-human pharmacokinetic and pharmacodynamic data were presented at AACR 2026. The company is raising money from the public through a Regulation A+ offering. Its first registered cancer trial, NCT06801002, was posted on ClinicalTrials.gov in January 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Jabez Bioscience
- HQ: Zionsville, IN
- Type: biotech
- Website: https://www.jabezbio.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026.
- The company's website is written largely as an investment solicitation; its claims about efficacy and market size are not repeated here.
- DHODH inhibition is filed under the metabolic therapy technology record because it starves cancer cells of pyrimidine nucleotides; there is no dedicated record.
- No financing round with an amount was read.

## Sources

- Official website: https://www.jabezbio.com/
- First patient dosed, April 2025: https://www.jabezbio.com/2025/04/03/jabez-biosciences-inc-announces-first-patient-dosed-in-phase-1-oncology-clinical-study-of-jbz-001/
- ClinicalTrials.gov: phase 1 trial of JBZ-001 (NCT06801002): https://clinicaltrials.gov/study/NCT06801002

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Metabolic therapy: starving the tumour of a nutrient](https://onco.cc/technologies/metabolic-therapy/)

---
JSON: https://onco.cc/api/v1/entities/jabez-biosciences.json